Kaleb Briscoe Brown, Ph.D. on X: "I will not be at #ASHE2023 this year as I am prioritizing my and my baby's health. I am so thankful for my friends and colleagues
![Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial - The Lancet Oncology Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/55e95fc9-92ae-472c-b3fd-9c4c1fb78cf8/gr1_lrg.gif)
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial - The Lancet Oncology
![Stacked Against, Part Two: Charge stacking and plea bargains in North Carolina – what you need to know - Carolina Public Press Stacked Against, Part Two: Charge stacking and plea bargains in North Carolina – what you need to know - Carolina Public Press](https://i0.wp.com/carolinapublicpress.org/wp-content/uploads/2023/05/Final_Consecutive-v-Concurrent-v-Consolidated-final.png?resize=780%2C650&ssl=1)